SignatureFD’s Prelude Therapeutics PRLD Stock Holding History

SignatureFD’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-992	Closed	-$7K	–	3295
2022 Q1	$7K	Buy	992 +764	+335%	+$6.99K	﹤0.01%	2357
2021 Q4	$3K	Buy	+228	New	+$3.71K	﹤0.01%	2609

Other funds holding PRLD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

SignatureFD's PRLD Position: Q2 2022 in Review

SignatureFD sold out of Prelude Therapeutics (PRLD) in Q2 2022, closing a stake of 992 shares — an estimated $7K sold.

SignatureFD first reported a position in PRLD in Q4 2021 and held it in 2 quarters. The position peaked at $7K in Q1 2022. 62 funds tracked by Wall St. Rank hold PRLD as of Q2 2022.

SignatureFD reported no remaining Prelude Therapeutics position as of Q2 2022 after selling out during the quarter.
SignatureFD sold 992 Prelude Therapeutics shares in Q2 2022, an estimated $7K.
SignatureFD first reported a position in Prelude Therapeutics in Q4 2021 and held it in 2 quarters.
SignatureFD's Prelude Therapeutics position peaked at $7K in Q1 2022.
62 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2022.

Based on SignatureFD's 13F filing for Q2 2022, filed 10 Aug 2022.